VAXCYTE, INC. Earnings Per Share, Basic and Diluted
VAXCYTE, INC. (PCVX) reported Earnings Per Share, Basic and Diluted of -$0.68 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- VAXCYTE, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.68.
- VAXCYTE, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.54.
- VAXCYTE, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.51.
- VAXCYTE, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.46.
- VAXCYTE, INC. earnings per share, basic and diluted for fiscal 2021 was -$1.93.
- VAXCYTE, INC. earnings per share, basic and diluted for fiscal 2020 was -$3.02.
- VAXCYTE, INC. earnings per share, basic and diluted for fiscal 2019 was -$13.25.
- VAXCYTE, INC. earnings per share, basic and diluted for fiscal 2018 was -$8.12.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.68 10-Q · filed 2022-05-09 | -$1.22 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.74 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$2.20 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2021-12-31 | -$0.54 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.05 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.51 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.93 10-K · filed 2022-02-28 |
| 2021-09-30 | -$0.51 10-Q · filed 2021-11-10 | -$0.97 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$1.39 10-Q · filed 2021-11-10 | -$1.79 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-06-30 | -$0.46 10-Q · filed 2021-08-11 | -$0.87 10-Q · filed 2021-08-11 | -$1.28 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.69 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-03-31 | -$0.41 10-Q · filed 2022-05-09 | -$0.82 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.23 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$2.02 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2020-12-31 | -$0.41 10-K · filed 2021-03-29 | -$0.82 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$3.02 10-K · filed 2022-02-28 |
| 2020-09-30 | -$0.41 10-Q · filed 2021-11-10 | -$1.32 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$3.06 10-Q · filed 2021-11-10 | -$4.70 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2020-06-30 | -$1.72 10-Q · filed 2021-08-11 | -$5.99 10-Q · filed 2021-08-11 | -$9.40 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$12.40 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2020-03-31 | -$6.70 10-Q · filed 2021-05-11 | -$10.42 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$13.41 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$16.39 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2019-12-31 | -$3.69 10-K · filed 2021-03-29 | -$6.63 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$9.54 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$13.25 10-K · filed 2022-02-28 |
| 2019-09-30 | -$2.93 10-K · filed 2021-03-29 | -$5.83 derived: net income ÷ weighted average shares · filed 2021-03-29 | -$9.54 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$2.90 10-K · filed 2021-03-29 | -$6.62 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | -$3.72 10-K · filed 2021-03-29 | |||
| 2018-12-31 | -$8.12 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |